~~<i id='08E58BEE48'><strike id='08E58BEE48'><tt id='08E58BEE48'><pre id='08E58BEE48'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：Wikipedia 2025-09-14 21:39:16 - browse：9489

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Doulas covered by Medicaid under New York's new plan

entertainment

focus

leisure time

explore

entertainment

knowledge

AdobeCVSHealthispreparingtomakesignificantchangestoits2025MedicareAdvantageplans,whichcouldpotential

WSS

STAT series 'Denied by AI' wins major journalism prizes

DeSantis can now import cheaper drugs. But will Biden get credit?

The SUPPORT Act is critical to fighting the opioid crisis

HHS names first

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Designating disabled people as health disparity population is crucial

focus

explore

entertainment

United colonoscopy coverage change 'may cost lives,' doctors say

Obesity drug from Roche shows promise in early study

23andMe had bad news about my health. I wish a person had delivered it

Boston hospital trains restaurant workers on naloxone for overdoses

Hepatitis C has a cure — but many Americans still lack access to it

DeSantis can now import cheaper drugs. But will Biden get credit?

Medicare details structure of new drug price negotiation program

Boston hospital trains restaurant workers on naloxone for overdoses

Drug repurposing or repositioning? The language matters

Health and fitness trackers are measuring the wrong things

focus

STAT series 'Denied by AI' wins major journalism prizes

Generative AI mines health records to identify patients’ social needs

The White House hikes tariffs on plastic syringes made in China

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

DeSantis can now import cheaper drugs. But will Biden get credit?

The White House hikes tariffs on plastic syringes made in China

leisure time

explore

entertainment

knowledge